Undercutting efforts of precision medicine: roadblocks to minority representation in breast cancer clinical trials
- PMID: 34080093
- DOI: 10.1007/s10549-021-06264-x
Undercutting efforts of precision medicine: roadblocks to minority representation in breast cancer clinical trials
Abstract
Precision (or personalized) medicine holds great promise in the treatment of breast cancer. The success of personalized medicine is contingent upon inclusivity and representation for minority groups in clinical trials. In this article, we focus on the roadblocks for the African American demographic, including the barriers to access and enrollment in breast oncology trials, the prevailing classification of race and ethnicity, and the need to refine monolithic categorization by employing genetic ancestry mapping tools for a more accurate determination of race or ethnicity.
Keywords: African Americans; Ancestry informative markers; Oncology trials; Race/ethnicity classification.
References
-
- Saini G et al (2020) Quadruple-negative breast cancer: an uneven playing field. JCO Glob Oncol 6:233–237 - PubMed
-
- Nazha B et al (2019) Enrollment of racial minorities in clinical trials: old problem assumes new urgency in the age of immunotherapy. Am Soc Clin Oncol Educ Book 39:3–10 - PubMed
-
- Phan VH et al (2009) Ethnic differences in drug metabolism and toxicity from chemotherapy. Expert Opin Drug Metab Toxicol 5(3):243–257 - PubMed
-
- Clements JM et al (2020) Disparities in diabetes-related multiple chronic conditions and mortality: the influence of race. Diabetes Res Clin Pract 159:107984 - PubMed
-
- Zilbermint M et al (2019) Genetics of hypertension in African Americans and others of African descent. Int J Mol Sci 20(5):1081 - PMC
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical